What is the mechanism of action of this treatment?

Targeted therapies and small molecule inhibitors, such as ICP-723, work by specifically targeting molecular pathways that are essential for tumor cell growth and survival. These treatments often inhibit proteins or enzymes that are mutated or overexpressed in cancer cells, thereby blocking signals that promote tumor proliferation and survival. This precision reduces damage to normal cells, leading to fewer side effects compared to traditional chemotherapy. For solid tumor patients, this targeted approach can result in more effective treatment outcomes and improved quality of life, as it directly interferes with the cancer's specific biological mechanisms.

What side effects are associated with this type of intervention?

Targeted therapies and small molecule inhibitors for solid tumors, such as those being studied in the ICP-723 trial, commonly cause side effects including gastrointestinal issues (nausea, diarrhea), skin reactions (rash, hand-foot syndrome), fatigue, hypertension, and hematologic toxicities (neutropenia, thrombocytopenia). The severity and frequency of these side effects can vary based on the specific drug and patient characteristics.

What prior FDA approvals exist?

The FDA has approved several targeted therapies and small molecule inhibitors for the treatment of solid tumors. Notable examples include imatinib (Gleevec) for gastrointestinal stromal tumors (GIST), erlotinib (Tarceva) for non-small cell lung cancer (NSCLC) with EGFR mutations, and vemurafenib (Zelboraf) for melanoma with BRAF V600E mutations. These drugs work by specifically targeting molecular abnormalities in cancer cells, thereby inhibiting tumor growth and progression. The trial of ICP-723 aims to evaluate a similar approach in patients with advanced solid tumors who have exhausted standard treatment options.

What other types of research exist?

Promising novel alternatives to ICP-723 for solid tumors include: <ol> <li>Regorafenib: Demonstrated efficacy and safety in metastatic osteosarcoma (Phase II studies).</li> <li></li> </ol> Cabozantinib: Shown promise in advanced Ewing sarcoma and osteosarcoma (Phase II trial). 3. Sorafenib: Evaluated in relapsed and unresectable high-grade osteosarcoma (Italian Sarcoma Group study). 4. Pembrolizumab: Used in combination with chemotherapy for metastatic non-small-cell lung cancer (KEYNOTE studies). 5. Nivolumab plus Ipilimumab: Effective in malignant pleural mesothelioma (CheckMate 743 trial).

← Back to Search

Other

ICP-723 for Advanced Cancer

Phase 1

Waitlist Available

Led By Jun Zhang

Research Sponsored by InnoCare Pharma Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing a new drug called ICP-723. It is aimed at patients with advanced solid tumors who have not responded to other treatments or have no other options. The study will adjust the dose over time to see if it is safe and how well patients can tolerate it.

Who is the study for?

Adults aged 18-80 with advanced solid tumors that can't be removed or have spread and don't respond to standard treatments may join. They should have measurable tumors, adequate organ function, and stable brain tumors if present. Those with significant digestive/neurological issues, recent major surgery, uncontrolled diseases, heart problems, or other active cancers in the last 5 years are excluded.

What is being tested?

The trial is testing ICP-723's safety and how the body processes it in patients whose solid tumors haven't responded to standard care. It involves gradually increasing doses to find a safe level while monitoring participants' reactions.

What are the potential side effects?

While specific side effects of ICP-723 aren't listed here, common ones for cancer drugs include nausea, fatigue, risk of infection due to low blood cell counts, liver or kidney function changes; detailed risks will be monitored throughout the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: ICP-723Experimental Treatment1 Intervention

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Targeted therapies and small molecule inhibitors, such as ICP-723, work by specifically targeting molecular pathways that are essential for tumor cell growth and survival. These treatments often inhibit proteins or enzymes that are mutated or overexpressed in cancer cells, thereby blocking signals that promote tumor proliferation and survival. This precision reduces damage to normal cells, leading to fewer side effects compared to traditional chemotherapy. For solid tumor patients, this targeted approach can result in more effective treatment outcomes and improved quality of life, as it directly interferes with the cancer's specific biological mechanisms.